People

Intranasal epinephrine developer Bryn Pharma announced that former Aerami Therapeutics Chief Operating Officer Joshua Ziel has joined the company as CEO, succeeding Sandy Loreaux. Prior to joining Aerami in 2022, Ziel held management positions at Syneos Health and at advertising agency WPP. According to the company, Loreaux has resigned as CEO due to family matters … [Read more...] about Joshua Ziel joins Bryn Pharma as CEO

Inhaled drug developer Transpire Bio has announced the hires of Timothy Lutz as VP of Manufacturing and Operations; Stuart Loesch as Chief Commercial Officer; and Todd Sunstrom as Head of Quality Assurance. The company recently announced the initiation of a Phase 1 trial for a generic inhaler for asthma and COPD. Last October, Transpire officially opened its new … [Read more...] about Transpire Bio names new VP of Manufacturing & Operations, Chief Commercial Officer, and Head of Quality Assurance

UK-based Synairgen, which is developing SNG001 inhaled interferon-beta-1a, announced that former Chiesi Global Head of Drug Development Mark Parry-Billings will succeed Simon Shaw as Chairman of the Board. Shaw will retire in October 2024. Prior to joining Chiesi in 2011, Parry-Billings was CEO of Topigen Pharmaceuticals, which was sold to Pharmaxis in 2010. His … [Read more...] about Synairgen names Mark Parry-Billings as new Chairman of the Board

Nasal drug developer Leyden Laboratories announced that former Moderna vaccine development executive Jintanat Ananworanich has joined the company as Chief Medical Officer. Ananworanich was most recently Executive Director of clinical development at Moderna, and her previous experience includes roles as Clinical Development Leader at the Bill and Melinda Gates Medical … [Read more...] about Leyden Labs names Jintanat Ananworanich as new Chief Medical Officer

Nocion Therapeutics, whose taplucainium (NTX-1175) DPI is in Phase 2 development for the treatment of chronic cough, has announced the appointments of two former Bellus Health executives, naming Catherine Bonuccelli to the scientific advisory board and Joan Shaw as Senior VP, Clinical Operations. Both were involved in the clinical development of Bellus' camlipixant … [Read more...] about Nocion announces appointments of Catherine Bonuccelli and Joan Shaw

Cardiff Scintigraphics, has announced the appointment of OINDP expert John Pritchard as the company's Chairman of the Board, succeeding David Owen. The news comes soon after Cardiff Scintigraphics, the parent company of inhalation CRO i2c Pharma Services, named Andrew Brown as CEO, succeeding Glyn Taylor. Pritchard, the 2018 winner of the Charles G. Thiel Award for … [Read more...] about Cardiff Scintigraphics names John Pritchard as Chairman of the Board

Disposable dry powder inhaler developer 1nhaler has announced the appointment of former AstraZeneca VP Jane Gaddum as Board Chair and non-executive director and former GSK VP Gordon Muirhead as a non-executive director. Gaddum was AstraZeneca VP of Global Marketing for Emerging Respiratory and Inflammation from 1997 to 2013, according to her LinkedIn profile. … [Read more...] about 1nhaler announces board appointments

UK-based Enterprise Therapeutics, which is developing inhaled ENaC blockers for the treatment of cystic fibrosis and other respiratory conditions, has named former Insmed Executive VP of Development and Chief Medical Officer Renu Gupta as the company's new CMO. Enterprise also announced the appointment of Janet Hammond, currently Chief Development Officer at Atea … [Read more...] about Enterprise Therapeutics names Renu Gupta as Chief Medical Officer

Cardiff Scintigraphics, the parent company of inhalation CRO i2c Pharma Services, has named former OBG Pharmaceuticals Chief Scientific Officer Andrew Brown as CEO, succeeding Glyn Taylor, who will continue part time as Chief Scientific Officer. Brown was most recently Chief Scientific Officer and Operations Director of OBG subsidiary Noveayr Therapeutics, which … [Read more...] about Cardiff Scintigraphics / i2c name Andrew Brown as CEO